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Background
The HIV-1 envelope glycoprotein (Env) employs multiple
mechanisms to escape from neutralizing antibodies
(NAbs), including insertions in the variable domains of
the gp120 subunit, and an increase in the density of the
glycan shield. Here, we analyzed whether the resistance of
Env to antibody neutralization has altered over the course
of the epidemic.
Methods
We determined the neutralization sensitivity to HIVIg and
the gp120-directed broadly neutralizing antibodies
(BNAbs) b12 and 2G12 of clonal HIV-1 variants isolated
from patients presenting with primary HIV-1 infection in
Amsterdam between either 1985 - 1988 or 2003 - 2005.
Moreover, we analyzed the length and glycosylation char-
acteristics of gp120 of historical and recent HIV-1 variants,
as well as the breadth of the neutralizing serum activity of
historical and recent seroconverters in the Amsterdam
Cohort.
Results
Viruses from recent seroconverters were more resistant to
neutralization by HIVIg than viruses from historical sero-
converters, but not to neutralization by BNAbs b12 or
2G12. The enhanced neutralization resistance of recent
viruses coincided with an increased length of the variable
loops in envelope, in particular the V1 loop, and an
increased density of the viral glycan shield. Similar
changes were observed between historical and contempo-
rary subtype B and subtype C gp120 sequences of the Los
Alamos database. In addition, historical seroconverters
developed broader NAb responses than more recent sero-
converters.
Conclusion
These finding suggest that over a period of 20 years, HIV-
1 has evolved towards a decreased exposure of antibody
epitopes by enhancing the masking mechanisms of its
envelope, although the epitopes of the gp120-direced
BNAbs b12 and 2G12 seem to be preserved. The increased
protection of Env against Abs appears to result in a
blunted NAb response, suggesting that Env from historical
viruses may be more promising immunogens for vaccine
design than Env from currently circulating, neutralization
resistant, HIV-1 variants.
from AIDS Vaccine 2009
Paris, France. 19-22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P389 doi:10.1186/1742-4690-6-S3-P389
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P389
© 2009 Bunnik et al; licensee BioMed Central Ltd. 